IVC Filter Efficacy in Patients With Cancer and Deep Vein Thrombosis: Rahul A. Sheth, MD

Patients with cancer are at substantially increased risk for deep vein thrombosis (DVT) and resulting pulmonary embolism. Together, these two forms of venous thromboembolism constitute the second leading cause of death for patients with known malignancies. The standard of care for DVT is anticoagulation, yet many patients with cancer and DVT are unable to receive anticoagulation because of the bleeding risk that it poses. In a study recently published in JAMA Internal Medicine, a team of investi...
Continue reading

Breast Cancer Chemotherapy in Older Patients With Comorbidities: Nina Tamirisa, MD

Many older patients with breast cancer have significant comorbidities, increasing the challenges of treatment. These challenges are compounded by the fact that elderly patients with multiple comorbidities are frequently excluded from participating in clinical trials, resulting in a lack of treatment data for this population. Nina Tamirisa, MD, and colleagues recently published a study in JAMA Oncology reporting that in older patients with multiple comorbidities and estrogen receptor–positive, no...
Continue reading

Delivering Immunotherapeutics Intratumorally: Safe for Treating Cancer?

Intravenous administration of chemotherapy is the conventional method of delivery. However, several issues arise with this method, including insufficient drug penetration into the tumor tissue. Intratumoral injections of immunotherapies directly into the tumor have been a possible solution to this problem, and, according to a recent study, results of which are published in JAMA Network Open, this technique has been found to be a viable option for a variety of histological conditions and target o...
Continue reading

First CAR T-Cell Therapy Approved for Mantle Cell Lymphoma

The FDA has now granted accelerated approval to brexucabtagene autoleucel (TecartusTM, Kite Pharma, formerly known as KTE-X19) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL). Brexucabtagene autoleucel, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, is the first CAR T-cell therapy approved for this rare type of B-cell non-Hodgkin lymphoma. Efficacy was evaluated in the multicenter, open-label phase 2 ZUMA-2 trial (NCT02601313), which enrolled 7...
Continue reading

In Cancer Patients With DVT, IVC Filter Reduces Pulmonary Embolism Risk

A new study finds that for patients with cancer and deep vein thrombosis (DVT), placement of an inferior vena cava (IVC) filter reduces the risk of pulmonary embolism. Venous thromboembolism (VTE) poses a substantial problem for patients with cancer: it occurs four to seven times more frequently in this population, and it is the second overall leading cause of death for patients with known malignancies. Pulmonary embolism is a potentially deadly condition that can develop as a result of VTE, and...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.